Understanding Mucus, Inflammation and Infection in COPD

Chronic bronchitis (CB) often coexists with chronic obstructive pulmonary disease (COPD), compounding the disease burden by worsening lung function.¹ While adult CB can occur independently of airway obstruction, its prevalence tends to rise with increasing severity of obstruction.¹

In this on-demand video, Professor Dave Singh explores the pathophysiology that leads to CB. He begins by explaining the inflammatory processes in COPD, including how smoking contributes to epithelial remodelling. He then examines airway mucus function and dysfunction, associated inflammatory mediators, and bacterial colonisation in the lungs.

Please also consider watching the on-demand video ‘COPD, Chronic Bronchitis and Exacerbations’ by Professor Wisia Wedzicha, which covers the definitions and prevalence of CB, as well as its impact on exacerbations and patient outcomes.

References

1. Mejza, F.; Nastalek, P.; Mastalerz-Migas, A.; Doniec, Z.; Skucha, W. Coexistence of Chronic Bronchitis in Chronic Obstructive Lung Disease. Adv. Exp. Med. Biol. 2018, 1114, 1–9.

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

• Professor Dave Singh

  Professor of Clinical Pharmacology and Respiratory Medicine

  Read biography
  Professor Dave Singh

  Professor of Clinical Pharmacology and Respiratory Medicine University of Manchester, UK

  Role and Location
  Dave Singh is Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, UK. He is the medical director of the Medicines Evaluation Unit, where he has acted as principal investigator in over 400 clinical trials.

  Education
  He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine.

  Memberships
  He is a member of the GOLD Science Committee. He was previously the chair of the European Respiratory Society airway pharmacology group. He is currently an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society.

  Research
  His research interest is the development of new drugs for asthma and COPD. He has over 450 publications.